Tony Taldone

TL;DR: It is suggested that progerin-induced aging can be used to reveal late-onset age-related disease features in hiPSC-based disease models.

TL;DR: This review summarizes the current status of both first and second generation HSP90 inhibitors based on their chemical classification and stage of clinical development and discusses the pharmacodynamic assays currently implemented in clinic as well as other novel strategies aimed at enhancing the effectiveness of Hsp90 inhibitors.

TL;DR: The results identify Hsp90 as a critical and multimodal target in this most difficult to treat breast cancer subtype and support the use of the Hsp 90 inhibitor PU-H71 for clinical trials involving patients with TNBC.

TL;DR: A review of small-molecule inhibitors of Hsp90 of diverse chemotypes that have shown potent antitumor activity in a wide-range of malignancies, and are currently in clinical or late-stage preclinical investigation.

TL;DR: This work uses PU-H71 affinity capture to design a proteomic approach that, when combined with bioinformatic pathway analysis, identifies dysregulated signaling networks and key oncoproteins in chronic myeloid leukemia and shows that this method can provide global insights into the biology of individual tumors, including primary patient specimens.